It Takes A Village
It is said that the journey is the reward. Our journey began in 2009 by understanding the critical unmet need for patient stratification in treating Triple Negative Breast Cancer (TNBC). The medical community had been successful in creating stratification tests for ER+ and HER2+ Breast Cancer, yet TNBC stratification remained elusive. Over the years we have been helped by so many in the medical community who shared our passion for cracking the code of TNBC stratification. Our current team is now focused on making BA100 Triple Negative Breast Cancer Stratification Test available across the globe. While the journey to this point has indeed been rewarding, we are only just beginning to realize the Patient benefit of eight years in relentless pursuit of solving this problem. Please see our current team of leaders and advisors below.
We are always looking for clinical advisors to join the Bioarray team. If you are interested in joining us, please click the button below.
Meet Our Executive Team
Board of Directors
Marcia Fournier, CEO & Founder
Pamela Layton, COO & President
Jim LaFrance, Executive Chairman
We are standing on the shoulders of giants. Without the support of these amazing partners, we would not have been able to bring BA100 – the worlds first and only triple negative breast cancer stratification test – to the world. Thank you!
“Triple Negative Breast Cancer Patients and Oncologists are holding us accountable to solve the previously unsolvable. It is our commitment to them that binds us as a team to create something that has never been done before and make it available across the globe.”